Operating
Other Working Capital
Neurocrine Biosciences Other Working Capital decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $700.00K to $0.00. Over 2 years (FY 2021 to FY 2024), Other Working Capital shows an upward trend with a -81.7% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ1 2016
Last reportedQ1 2026May 5, 2026
How to read this metric
Large fluctuations may indicate timing differences in tax payments, accruals, or other non-core operational shifts.
Detailed definition
Captures the net impact of changes in operating assets and liabilities not categorized as accounts receivable, inventory...
Peer comparison
Varies significantly by industry; peers with similar business models should show comparable trends in accrual management.
Metric ID:
change_in_other_working_capitalHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.00M | $2.10M | -$10.70M | $800.00K | $1.50M | $700.00K | -$100.00K | -$200.00K | -$300.00K | $1.30M | $3.40M | -$3.40M | $0.00 | $100.00K | $700.00K | $200.00K | $0.00 |
| QoQ Change | — | -30.0% | -609.5% | +107.5% | +87.5% | -53.3% | -114.3% | -100.0% | -50.0% | +533.3% | +161.5% | -200.0% | +100.0% | — | +600.0% | -71.4% | -100.0% |
| YoY Change | — | — | — | — | -50.0% | -66.7% | -112.5% | -113.3% | -142.9% | — | >999% | <-999% | +100.0% | -92.3% | -79.4% | — | -100.0% |
Range-$10.70M – $3.40M
CAGR-100.0%
Avg YoY Growth+113.0%
Median YoY Growth-92.3%
Current Streak2 quarters decline
Other Working Capital at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's other working capital?
- Neurocrine Biosciences (NBIX) reported other working capital of $0.00 in Q1 2026.
- How has Neurocrine Biosciences's other working capital changed year-over-year?
- Neurocrine Biosciences's other working capital decreased by 100.0% year-over-year, from $700.00K to $0.00.
- What is the long-term trend for Neurocrine Biosciences's other working capital?
- Over 2 years (2021 to 2024), Neurocrine Biosciences's other working capital has grown at a -81.7% compound annual growth rate (CAGR), from -$3.00M to $100.00K.
- What does other working capital mean?
- Net cash impact from changes in miscellaneous operating assets and liabilities.